Evidence map›Paper›PMID 31405866›Full record

Trial reportAntimicrobial agents and chemotherapy2019

A Randomized Open-Label Evaluation of the Antimalarial Prophylactic Efficacy of Azithromycin-Piperaquine versus Sulfadoxine-Pyrimethamine in Pregnant Papua New Guinean Women.

Brioni R Moore, John M Benjamin, Roselyn Tobe, Maria Ome-Kaius, Gumul Yadi, Bernadine Kasian, Charles Kong, Leanne J Robinson, Moses Laman, Ivo Mueller and 2 more

Open access · bronzeAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Antimicrobial agents and chemotherapy, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Revisiting Azithromycin for Intermittent Preventive Treatment in Pregnancy.The American journal of tropical medicine and hygiene · 2025
    Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 3 countries.

Brioni R MooreSchool of Pharmacy and Biomedical Sciences, Curtin University, Bentley, Australia.
John M BenjaminVector Borne Disease Unit, Papua New Guinea Institute of Medical Research, Madang, Papua New Guinea.
Roselyn TobeVector Borne Disease Unit, Papua New Guinea Institute of Medical Research, Madang, Papua New Guinea.
Maria Ome-KaiusVector Borne Disease Unit, Papua New Guinea Institute of Medical Research, Madang, Papua New Guinea.
Gumul YadiVector Borne Disease Unit, Papua New Guinea Institute of Medical Research, Madang, Papua New Guinea.
Bernadine KasianVector Borne Disease Unit, Papua New Guinea Institute of Medical Research, Madang, Papua New Guinea.
Charles KongVector Borne Disease Unit, Papua New Guinea Institute of Medical Research, Madang, Papua New Guinea.
Leanne J RobinsonVector Borne Disease Unit, Papua New Guinea Institute of Medical Research, Madang, Papua New Guinea.
Moses LamanMedical School, The University of Western Australia, Crawley, Australia.
Ivo MuellerPopulation Health and Immunity Division, Walter and Eliza Hall Institute, Parkville, Australia.
Stephen RogersonDepartment of Medicine, The Peter Doherty Institute for Infection and Immunity, University of Melbourne, Parkville, Australia.
Timothy M E DavisMedical School, The University of Western Australia, Crawley, Australia tim.davis@uwa.edu.au.ORCID 0000-0003-0749-7411
Papua New Guinea Institute of Medical Research · PGThe University of Western Australia · AUThe University of Melbourne · AUBurnet Institute · AUInstitut Pasteur · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Emerging malaria parasite sulfadoxine-pyrimethamine (SP) resistance has prompted assessment of alternatives for intermittent preventive treatment in pregnancy (IPTp). The objective was to evaluate the tolerability and prophylactic efficacy of azithromycin (AZ) plus piperaquine (PQ) in pregnant women in Papua New Guinea. The study was an open-label, randomized, parallel-group trial. A total of 122 women (median gestation, 26 weeks [range, 14 to 32 weeks]) were randomized 1:1 to three daily doses of 1 g AZ plus 960 mg PQ tetraphosphate or single-dose SP (4,500 mg sulfadoxine plus 225 mg pyrimethamine), based on computer-generated block randomization. Tolerability was assessed to day 7, and efficacy was assessed to day 42 (when participants were returned to usual care) and at delivery. Data for 119 participants (AZ-PQ,

Indexed as

AdultAntimalarialsAsymptomatic DiseasesAzithromycinChemopreventionDrug CombinationsErythrocytesFemaleGestational AgeHumansLive BirthMalaria, FalciparumMalaria, VivaxPapua New GuineaParasitemiaPiperazinesAntimalarialsAzithromycinDrug Combinationsfanasil, pyrimethamine drug combinationpiperaquinePiperazinesPyrimethamineQuinolinesSulfadoxineazithromycinefficacymalariapiperaquinepregnancytolerability

Identifiers

PMID31405866
PMCPMC6761509
OpenAlexW2964908665

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.